Is a Combination of a GnRH Agonist and Recombinant Growth Hormone an Effective Treatment to Increase the Final Adult Height of Girls with Precocious or Early Puberty?

Int J Endocrinol · 2018 · PMC6332953 · PMID 30693027

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The overall analysis showed that the difference between FAHSDS and initial HSDS in the test cohorts was 0.31 SDS lower than that in the control cohorts (95% CI = −0.73–0.11, Z = 1.45, P = 0.15), although this did not reach statistical significance (Job et al.

also in 111,027 other papers

borderline significantno p-value reported

When data from these two studies of ICPP were pooled (heterogeneity test: Q = 0.08, df = 1, P = 0.77, I 2 = 0%), the overall analysis showed that the difference between FAHSDS and initial HSDS in the experimental cohorts was 0.4 SDS higher than in the control cohorts (95% CI = −0.01–0.81, Z = 1.94, P = 0.05), a borderline significant result ( Figure 4(c) ). 4.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.